my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
24-09-2007: IMAGNA (immuno gene therapy with magnetic nanoparticles) has been founded by members of the Inst. of Experimental Oncology Klinikum rechts der Isar (Technical University Munich), the Clinic of Small Animal Medicine of the Ludwig-Maximilians-Universität , Bayer Schering Pharma AG, chemicell GmbH, and PlasmidFactory GmbH & Co. KG to provide evidence for the usefulness of therapeutic tumor vaccination by the Magnetofection technology in a clinical study in cats with fibrosarcoma. This consortium is supported by a grant from the German Ministry of Education and Research (BMBF).
Standard therapy for cat fibrosarcoma is surgical removal. However, the tumor recurs in 75% of the patients within one year. The IMAGNA team has used Magnetofection to guide cytokine genes directly into the tumor prior to surgical excision. The idea was that the cytokine expression within the tumor mass might activate the immune system against the tumor so that tumor cells missed by the surgical procedure would be killed.
Preliminary results indicate that anti cancer immune therapy with Magnetofection reduces the relapse of cat fibrosarcoma from 75% to nearly 40%. Additional studies are intended to confirm and extend these promising preliminary results and to take initial steps towards a future drug approval, firstly for the veterinary medicine.
The partners contribute with their different competences in the field of veterinary medicine, therapeutic anti cancer vaccination, DNA production, gene transfer and targeting, pharmaceutical manufacturing and regulation.
Watchlist
This is where you can add this news to your personal favourites
IMAGNA project team started work on therapeutic vaccination against cat fibrosarcoma
IMAGNA (immuno gene therapy with magnetic nanoparticles) has been founded by members of the Inst. of Experimental Oncology Klinikum rechts der Isar (Technical University Munich), the Clinic of Small Animal Medicine of the Ludwig-Maximilians-Universität , Bayer Schering Pharma AG, chemicell ... more
chemicell develops and produces innovative bioseparation- gene transfection and detection systems based on magnetic nano- and microparticles. Focus of our product development is to design high quality customer-oriented "ready-to use" kits with special orientation towards the compatibility f ... more
PlasmidFactory: New production facility successfully put into operation
PlasmidFactory's new facility for the production of high purity plasmid DNA is now operating successfully in new, modern labs. Plasmid DNA of the highest quality is being produced in the new premises in accordance with the EMEA guideline CHMP/BWP/2458/03. To ensure product safety, substance ... more
IMAGNA project team started work on therapeutic vaccination against cat fibrosarcoma
IMAGNA (immuno gene therapy with magnetic nanoparticles) has been founded by members of the Inst. of Experimental Oncology Klinikum rechts der Isar (Technical University Munich), the Clinic of Small Animal Medicine of the Ludwig-Maximilians-Universität , Bayer Schering Pharma AG, chemicell ... more
PlasmidFactory obtained worldwide license from DKFZ for manufacture of pDG helper/packaging vectors
PlasmidFactory has obtained a worldwide license from the German Cancer Research Center DKFZ for the manufacture and the marketing of the pDG helper/packaging vector series used for adeno-associated virus (AAV) production. The license agreement extends to multiple vector serotypes such as p ... more
Fascinating rhythm: The brain's 'slow waves'
New findings clarify where and how the brain's "slow waves" originate. These rhythmic signal pulses, which sweep through the brain during deep sleep at the rate of about one cycle per second, are assumed to play a role in processes such as consolidation of memory. For the first time, resear ... more
A highly effective poison kills the larvae of the garden chafer when the threadworm Heterorhabditis lays its eggs in it. Until now it was a mystery why the much larger larvae die, while the threadworms survive the poison unharmed. Scientists at the Technische Universitaet Muenchen (TUM) hav ... more
Individual protein complex generates electric current
An team of scientists, led by Joachim Reichert, Johannes Barth, and Alexander Holleitner (Technische Universitaet Muenchen, Clusters of Excellence MAP and NIM), and Itai Carmeli (Tel Aviv University) developed a method to measure photocurrents of a single functionalized photosynthetic prote ... more
Technische Universität München
Since its inception in 1868, TUM has established its reputation as a foremost academic institution with 6 Nobel prizes and many other prestigious awards, making it repeatedly the number one German university in various rankings, including the most recent ones. Our university covers a large ... more
Jülich researchers contribute to "Human Brain Project"
To understand the human brain using simulation – that’s the vision of the Human Brain Project (HBP). In order to make it a reality, researchers from 23 countries are working together to build a unique infrastructure that will allow them to establish and further develop a brain research and ... more
BRAIN to lead the NatLifE 2020 industrial innovation alliance
BRAIN AG has announced that the Natural Life Excellence Network 2020 (NatLifE 2020) innovation alliance will be funded by the Federal Ministry of Education and Research (BMBF) under the “Industrial Biotechnology Innovation Initiative” scheme. The official announcement has been made by Perma ... more
Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin Program
Pieris AG announced the receipt of a EUR 1 million grant to support the development of the company’s proprietary PRS-110 compound targeting c-Met, a cellular receptor that plays a key role in cancer cell growth and metastasis. The goal of the funded research will be to delineate a biomarker ... more
Bundesministerium für Bildung und Forschung (BMBF)
Education forms the basis for one's whole life; research opens up previously unknown opportunities in all fields of life. Education and research need perspectives which extend far into the future. These are the foundations on which our future evolves. The BMBF's promotion of education and r ... more
Damage to the genomic DNA may endanger the whole organism. A new study shows that in the fruit fly Drosophila melanogaster RNA transcripts derived from DNA sequences that have been disrupted by double-strand breaks end up in a deadly embrace. The double-stranded genomic DNA in each cell is ... more
Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announces the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagno ... more
A possible new target for treatment of multiple sclerosis
The immune system recognizes and neutralizes or destroys toxins and foreign pathogens that have gained access to the body. Autoimmune diseases result when the system attacks the body's own tissues instead. One of the most common examples is multiple sclerosis (MS). MS is a serious condition ... more
The Lead Discovery Center GmbH (LDC), based in Dortmund, Germany, a spin-off from Max-Planck-Innovation GmbH (MI) in Munich, with expertise in small molecule pharmaceutical drug discovery, has successfully licensed its first lead structure to a pharma partner. The agreement grants Bayer Sch ... more
EU regulators okay Qlaira for the treatment of heavy menstrual bleeding
Bayer Schering Pharma AG, Germany, has successfully concluded the European registration procedure for the introduction of Qlaira in the new indication treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. The Netherlands served as Reference ... more
Bayer launches Betaferon in China
Bayer Schering Pharma announced the upcoming launch in China of Betaferon® (interferon beta-1b) for the treatment of relapsing-remitting forms of multiple sclerosis (MS). Betaferon is already approved in over 100 countries worldwide. With Betaferon and Gadovist®1.0, which was also recently ... more
Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more
Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
